218 related articles for article (PubMed ID: 31022985)
1. MicroRNAs Mediated Regulation of Expression of Nucleoside Analog Pathway Genes in Acute Myeloid Leukemia.
Bhise NS; Elsayed AH; Cao X; Pounds S; Lamba JK
Genes (Basel); 2019 Apr; 10(4):. PubMed ID: 31022985
[TBL] [Abstract][Full Text] [Related]
2. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.
Abraham A; Varatharajan S; Karathedath S; Philip C; Lakshmi KM; Jayavelu AK; Mohanan E; Janet NB; Srivastava VM; Shaji RV; Zhang W; Abraham A; Viswabandya A; George B; Chandy M; Srivastava A; Mathews V; Balasubramanian P
Pharmacogenomics; 2015 Jul; 16(8):877-90. PubMed ID: 26083014
[TBL] [Abstract][Full Text] [Related]
3. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.
Yamauchi T; Negoro E; Kishi S; Takagi K; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
Biochem Pharmacol; 2009 Jun; 77(12):1780-6. PubMed ID: 19428333
[TBL] [Abstract][Full Text] [Related]
4. Genetic factors influencing cytarabine therapy.
Lamba JK
Pharmacogenomics; 2009 Oct; 10(10):1657-74. PubMed ID: 19842938
[TBL] [Abstract][Full Text] [Related]
5. Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells.
Song JH; Kim SH; Kweon SH; Lee TH; Kim HJ; Kim HJ; Kim TS
Int J Oncol; 2009 Apr; 34(4):1165-71. PubMed ID: 19287976
[TBL] [Abstract][Full Text] [Related]
6. [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine].
Xie XT; Jiang SY; Li BS; Yang LL
Zhonghua Er Ke Za Zhi; 2008 Apr; 46(4):276-80. PubMed ID: 19099730
[TBL] [Abstract][Full Text] [Related]
7. Expression Levels of Human Equilibrative Nucleoside Transporter 1 and Deoxycytidine Kinase Enzyme as Prognostic Factors in Patients with Acute Myeloid Leukemia Treated with Cytarabine.
Candelaria M; Corrales-Alfaro C; Gutiérrez-Hernández O; Díaz-Chavez J; Labardini-Méndez J; Vidal-Millán S; Herrera LA
Chemotherapy; 2016; 61(6):313-8. PubMed ID: 27119162
[TBL] [Abstract][Full Text] [Related]
8. Long noncoding RNA DANCR confers cytarabine resistance in acute myeloid leukemia by activating autophagy via the miR-874-3P/ATG16L1 axis.
Zhang H; Liu L; Chen L; Liu H; Ren S; Tao Y
Mol Oncol; 2021 Apr; 15(4):1203-1216. PubMed ID: 33638615
[TBL] [Abstract][Full Text] [Related]
9. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.
Schneider C; Oellerich T; Baldauf HM; Schwarz SM; Thomas D; Flick R; Bohnenberger H; Kaderali L; Stegmann L; Cremer A; Martin M; Lohmeyer J; Michaelis M; Hornung V; Schliemann C; Berdel WE; Hartmann W; Wardelmann E; Comoglio F; Hansmann ML; Yakunin AF; Geisslinger G; Ströbel P; Ferreirós N; Serve H; Keppler OT; Cinatl J
Nat Med; 2017 Feb; 23(2):250-255. PubMed ID: 27991919
[TBL] [Abstract][Full Text] [Related]
10. Effect of dexamethasone on the antileukemic effect of cytarabine: role of deoxycytidine kinase.
Jaramillo AC; Bergman AM; Comijn EM; Jansen G; Kaspers GJL; Cloos J; Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2020; 39(10-12):1346. PubMed ID: 32727269
[TBL] [Abstract][Full Text] [Related]
11. DNA Methylation-Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia.
Buelow DR; Anderson JT; Pounds SB; Shi L; Lamba JK; Hu S; Gibson AA; Goodwin EA; Sparreboom A; Baker SD
Clin Transl Sci; 2021 Jan; 14(1):137-142. PubMed ID: 32905646
[TBL] [Abstract][Full Text] [Related]
12. A bioluminescent microbial biosensor for in vitro pretreatment assessment of cytarabine efficacy in leukemia.
Alloush HM; Anderson E; Martin AD; Ruddock MW; Angell JE; Hill PJ; Mehta P; Smith MA; Smith JG; Salisbury VC
Clin Chem; 2010 Dec; 56(12):1862-70. PubMed ID: 20921267
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of in vivo cytarabine-induced gene expression signature in AML.
Lamba JK; Pounds S; Cao X; Crews KR; Cogle CR; Bhise N; Raimondi SC; Downing JR; Baker SD; Ribeiro RC; Rubnitz JE
Leuk Lymphoma; 2016; 57(4):909-20. PubMed ID: 26366682
[TBL] [Abstract][Full Text] [Related]
14. Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine.
Nishi R; Shigemi H; Negoro E; Okura M; Hosono N; Yamauchi T
BMC Cancer; 2020 Oct; 20(1):984. PubMed ID: 33046037
[TBL] [Abstract][Full Text] [Related]
15. Using genome-wide CRISPR library screening with library resistant DCK to find new sources of Ara-C drug resistance in AML.
Kurata M; Rathe SK; Bailey NJ; Aumann NK; Jones JM; Veldhuijzen GW; Moriarity BS; Largaespada DA
Sci Rep; 2016 Nov; 6():36199. PubMed ID: 27808171
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-143 sensitizes acute myeloid leukemia cells to cytarabine via targeting ATG7- and ATG2B-dependent autophagy.
Zhang H; Kang J; Liu L; Chen L; Ren S; Tao Y
Aging (Albany NY); 2020 Oct; 12(20):20111-20126. PubMed ID: 33077697
[TBL] [Abstract][Full Text] [Related]
17. Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia.
Degwert N; Latuske E; Vohwinkel G; Stamm H; Klokow M; Bokemeyer C; Fiedler W; Wellbrock J
Eur J Haematol; 2016 Sep; 97(3):239-44. PubMed ID: 26613208
[TBL] [Abstract][Full Text] [Related]
18. In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene.
Stegmann AP; Honders MW; Hagemeijer A; Hoebee B; Willemze R; Landegent JE
Ann Hematol; 1995 Jul; 71(1):41-7. PubMed ID: 7543292
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms at microRNA binding sites of Ara-C and anthracyclines-metabolic pathway genes are associated with outcome of acute myeloid leukemia patients.
Cao HX; Miao CF; Yan L; Tang P; Zhang LR; Sun L
J Transl Med; 2017 Nov; 15(1):235. PubMed ID: 29141648
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Nrf2-mediated glucose metabolism by brusatol synergistically sensitizes acute myeloid leukemia to Ara-C.
Cheng C; Yuan F; Chen XP; Zhang W; Zhao XL; Jiang ZP; Zhou HH; Zhou G; Cao S
Biomed Pharmacother; 2021 Oct; 142():111652. PubMed ID: 34112534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]